DR. PETER GERARD MILNER, MD
Osteopathic Medicine at Manuella Rd, Los Altos, CA

6818782, Nov 16, 2004

Oct 29, 2003

10/697683

Pascal Druzgala - Santa Rosa CA
Peter G. Milner - Los Altos Hills CA

ARYX Therapeutics - Los Altos Hills CA

C07D30778

549467, 549468

The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

2011013, Jun 9, 2011

Nov 23, 2010

12/952683

Peter G. Milner - Los Altos Hills CA, US
David Jack Ellis - Los Altos CA, US

A61K 31/397, A61K 31/40, A61K 31/4439, A61K 31/4709, A61K 31/4545, A61K 31/5377, A61K 31/444, A61K 31/4418, A61K 31/37, A61K 31/4402, A61K 31/445, A61K 31/439, A61P 9/00, A61P 7/02

51421017, 514424, 514338, 514314, 514303, 5142368, 514301, 514357, 514457, 514352, 514327, 514299

The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of multiple ion channel blocker and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of the multiple ion channel blocker may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.

2006004, Mar 2, 2006

Jun 27, 2005

11/167925

Pascal Druzgala - Santa Rosa CA, US
Peter Milner - Los Altos Hills CA, US
Jurg Pfister - Los Altos CA, US

Aryx Therapeutics, Inc. - Santa Clara CA

A61K 31/426, A61K 31/42, A61K 31/198, A61K 31/192

514369000, 514378000, 548183000, 548243000, 514563000, 514570000, 514571000, 562450000, 562465000

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

2011014, Jun 16, 2011

Nov 23, 2010

12/952696

Peter G. Milner - Los Altos Hills CA, US
David Jack Ellis - Los Altos CA, US

A61K 31/343, A61P 9/00

514469

The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration.

7041673, May 9, 2006

Jan 23, 2004

10/763904

Pascal Druzgala - Santa Rosa CA, US
Peter G. Milner - Los Altos Hills CA, US

ARYX Therapeutics, Inc. - Fremont CA

C07D 239/42, C07D 239/62, A61K 31/505, A61K 31/515, A61P 25/20

514270, 514272, 514302, 514320, 514321

The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.

6610825, Aug 26, 2003

Mar 1, 2001

09/798119

Alan M. Ezrin - Moraga CA
Dominique P. Bridon - Outremont, CA
Darren L. Holmes - Montreal, CA
Peter G. Milner - Los Altos Hills CA

ConjuChem, Inc. - Montreal

C07K 700

530327, 530324, 530325, 530326, 530362, 530363, 530380, 514 2, 514 12, 514 13, 514 14, 514 15

Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patients vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patients vascular system.

6706892, Mar 16, 2004

Sep 6, 2000

09/656121

Alan M. Ezrin - Moraga CA
Angelica Fleser - Montreal, CA
Martin Robitaille - Terrasse-Vaudreuil, CA
Peter G. Milner - Los Altos Hills CA
Dominique P. Bridon - Outremont, CA

Conjuchem, Inc. - Montreal

A61K 314015

548548, 544269, 544372, 546 93, 546208, 548520, 51425402, 514290, 514422, 514423, 514265, 514326, 514776, 424 45, 424489, 424 7817, 424 7837

Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.

2009017, Jul 9, 2009

Oct 31, 2007

11/982033

Dominique P. Bridon - Franklin MA, US
Alan M. Ezrin - Miami FL, US
Peter G. Milner - Los Altos Hills CA, US
Darren L. Holmes - Anaheim CA, US
Karen Thibaudeau - Rosemere, CA

A61K 38/38, C07K 19/00, A61K 38/21, A61K 38/28, A61K 38/22, A61K 38/18

424 855, 530362, 530351, 514 3, 514 12

A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

6316487, Nov 13, 2001

Oct 6, 2000

9/680880

Pascal Druzgala - Santa Rosa CA
Peter G. Milner - Los Altos Hills CA

Aryx Therapeutics - Los Altos Hill CA

A61K 31405, A61K 31381, A61K 3136, C07D20912, C07D33354

514419

The subject invention pertains to novel compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. The new compounds can have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The product can also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

2003021, Nov 20, 2003

Apr 18, 2003

10/418842

Pascal Druzgala - Santa Rosa CA, US
Peter Milner - Los Altos Hills CA, US
Jurg Pfister - Los Altos CA, US
Cyrus Becker - Menlo Park CA, US

A61K031/541, A61K031/5377, A61K031/496, A61K031/4545, A61K031/454

514/227800, 514/253120, 514/235500, 514/317000, 514/326000

The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.